Email Updates

Search form

You are here

Webinar & Meeting Reports

  • May 11, 2017

    Dr. Lynn Morris provided an overview of antibody research for HIV prevention. She laid out the current landscape; provided a glimpse of what is to come in this dynamic field; talked about where antibody work fits in the larger field of prevention research; and described how the Antibody Mediated Prevention (AMP) studies – ongoing proof-of-concept trials of the broadly neutralizing antibody VRC01 – might advance HIV prevention.

  • May 8, 2017

    Dr. Fatima Laher, protocol co-chair of HVTN 702, provides an overview of the first HIV vaccine efficacy trial in seven years. Her presentation looks at the history, starting with partial success of RV144 in 2009, and talks about the role HVTN 702 as the field advances toward an effective vaccine.

  • May 4, 2017

    Long-time vaccine researcher Barney Graham presented an excellent overview of the history and work of NIH’s Vaccine Research Center (VRC)—established two decades ago on the inaugural HIV Vaccine Awareness Day (HVAD) in 1997. Download the recording for an accessible overview of the HIV vaccine field, the connections between the work on HIV and other vaccines at the VRC and tips on what advocates and researchers should be calling for this HVAD.

  • April 28, 2017

    The HIV Vaccine Awareness Day 2017 webinar series kicked off with an overview of the Ad26/mosaic vaccine efficacy program from Janssen’s Maria Grazia Pau. This strategy is notable both for the science and for the active leadership from industry. Dr. Pau did a terrific job of explaining where the strategy fits into the broader vaccine field.

  • April 26, 2017

    In this webinar, we were joined by Dr. James Kiarie, coordinator of the Human Reproduction Team at the World Health Organization. Dr. Kiarie presented new guidance from WHO on hormonal contraceptive eligibility for women at high risk of HIV. He also fielded questions from webinar participants.

  • April 4, 2017

    Hundreds of people tuned in to hear researchers discuss the available data on “time to protection” required for effective oral PrEP with TDF/FTC—i.e., how many doses must be taken to build up protective levels of the drug in the blood? The answer is—it varies. Not surprisingly then, so do the guidelines for PrEP use.

  • March 20, 2017

    IPM, AVAC, Dalberg Design Impact Group and the USAID Center for Accelerating Innovation and Impact held a side event during the 61st session of the United Nations Commission on the Status of Women. The conversation brought together stakeholders working to advance women's empowerment by building bridges between global health and economic empowerment initiatives.

  • March 10, 2017

    In this call, panelists discussed what the WHO grading system for family planning methods is, what impact a change in classification for DMPA and NET-EN has for women, programs and research, and what needs to happen next.

  • February 13, 2017 to February 16, 2017

    The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases.

  • February 9, 2017

    There has been lots of discussion about the different PrEP guidelines with respect to how long it takes women to get protection with oral PrEP. This webinar tried to help us all understand the data that do exist and how the different guidelines emerged. The call featured pharmacologists who’ve generated much of the data to briefly present their data and interpretations. This was followed by a Q&A period.